A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Public ClinicalTrials.gov record NCT03755518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least a 35% reduction in spleen size and one of the secondary objectives is to evaluate the safety of fedratinib.
Study identification
- NCT ID
- NCT03755518
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2019 (Actual)
- Primary completion
- Nov 26, 2021 (Actual)
- Completion
- Nov 8, 2023 (Actual)
- Last update posted
- Dec 12, 2024
2019 – 2023
United States locations
- U.S. sites
- 28
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 117 | Aurora | Colorado | 80045 | — |
| Local Institution - 126 | Miami | Florida | 33176 | — |
| Local Institution - 113 | Augusta | Georgia | 30912 | — |
| Local Institution - 112 | Chicago | Illinois | 60612 | — |
| Local Institution - 109 | Chicago | Illinois | 60637 | — |
| Local Institution - 121 | Park Ridge | Illinois | 60068 | — |
| Local Institution - 100 | Kansas City | Kansas | 66160-7314 | — |
| Local Institution - 123 | Baltimore | Maryland | 21229-5299 | — |
| Local Institution - 118 | Bethesda | Maryland | 20817 | — |
| Local Institution - 127 | Columbia | Maryland | 21044 | — |
| Local Institution - 103 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 101 | St Louis | Missouri | 63110 | — |
| Local Institution - 128 | Newark | New Jersey | 07112-2027 | — |
| Local Institution - 130 | Brooklyn | New York | 11212 | — |
| Local Institution - 115 | New York | New York | 10029 | — |
| Local Institution - 124 | New York | New York | 10032 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Local Institution - 105 | Chapel Hill | North Carolina | 27514 | — |
| Local Institution - 114 | Durham | North Carolina | 27705 | — |
| Local Institution - 111 | Cincinnati | Ohio | 45219 | — |
| Local Institution - 106 | Pittsburgh | Pennsylvania | 15224 | — |
| Local Institution - 108 | Sioux Falls | South Dakota | 57105 | — |
| Local Institution - 119 | Dallas | Texas | 75390-8852 | — |
| Local Institution - 132 | Fort Worth | Texas | 76104 | — |
| Local Institution - 110 | Houston | Texas | 77303 | — |
| Local Institution - 120 | San Antonio | Texas | 78229 | — |
| Local Institution - 116 | Seattle | Washington | 98109 | — |
| Local Institution - 129 | Madison | Wisconsin | 53792-2454 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03755518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2024 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03755518 live on ClinicalTrials.gov.